Stakeholders offer competing views on how FDA should regulate generative AI in medtech
On November 3, industry stakeholders set out differing positions on how the FDA should regulate generative AI in medical technology. Five views show the main lines of the debate.
Who is affected and how
- medtech company
- Approval strategies for generative AI products must be adjusted as the FDA's approach evolves.
- health policy
- In shaping the regulatory framework, the challenge is balancing the differing interests of stakeholders.
Sources
- How should the FDA regulate generative AI in medtech? Here are 5 takesmedtech dive · Nov 3, 2026
- How should the FDA regulate generative AI in medtech? Here are 5 takes | Healthcare Divehealthcaredive.com · Nov 3, 2026
- How should the FDA regulate generative AI in medtech? Here are 5 takes | MedTech Divemedtechdive.com · Nov 3, 2026
- GenAI: Stakeholders offer competing views on FDA's regulatory approachraps · Nov 3, 2026
- GenAI: Stakeholders offer competing views on FDA's regulatory approach | RAPSraps.org · Nov 4, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.